About 10% of Jordan’s gross domestic product is spent on health care, almost one-third of which is spent on pharmaceuticals. Jordan’s pharmaceutical spending is a substantially higher percentage of gross domestic product than that of other developed countries. Generic substitution is a mechanism that could lower pharmaceutical spending costs in Jordan, but Jordan’s domestic law currently forbids pharmacists in the private market from dispensing generic equivalents to branded medicines without a physician’s approval. This article provides the results of a study that surveyed prominent organizational stakeholders (n = 17, RR 100%) in Jordan’s health care system and evaluates their opinions about generic substitution. The study finds there is a broad base of support for allowing and encouraging generic substitution in the private sector, and for mandating generic substitution in the public sector